The establishment of a brand-new office and
cutting-edge Illumina Solutions Center in Bengaluru, India, was announced by Illumina Inc., a leader in DNA sequencing and array-based technologies.
Illumina's growth comes after 16 years of tight collaboration with Premas Life Sciences, the company's channel partner in India. With its own permanent facility now, Illumina will keep working with Premas to expand the genomics market in India, which the UN considers to be the world's most populous nation with more than 1.4 billion inhabitants. The opening up of potential for improving healthcare and battling the consequences of climate change in South Asia will be made possible by extending access to genomics in this significant market.
"Expanding Illumina's presence in India allows the company to collaborate and be part of a vibrant biotech ecosystem with skilled labor, strong research and development resources, and supportive government policies," said Gretchen Weightman, Senior Vice President, Asia Pacific, Middle East & Africa, Illumina. "In our 25th anniversary year, it's a very exciting time to be growing our physical presence in India to drive access and the further adoption of genomics to transform human health, particularly in oncology and infectious disease."
Infectious disease of concern and a common issue in India is tuberculosis. Each year, about 500,000 new cases of TB are discovered worldwide, with India being responsible for 30% of those cases. Through the FIND Seq&Treat project, which aims to boost adoption of next-generation sequencing (NGS) for affordable, scalable, and quick TB drug-susceptibility testing, Illumina has assisted TB monitoring for the past seven years in India.
Along with philanthropic financing from the Bill & Melinda Gates Foundation and the Rockefeller Foundation to support COVID-19 surveillance, Illumina has also funded projects to improve access to sequencing capacity in India.
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
